Assessment of chronic myeloid leukemia patients' adherence with “tyrosine kinase inhibitors” in King Abdulaziz Medical City

CONTEXT: Worldwide, chronic myeloid leukemia (CML) accounts for 15% of all leukemia types. CML treatment and outcome has improved dramatically from the average survival of 3–5 years in the past to almost normal life expectancy with the new targeted therapy with tyrosine kinase inhibitors (TKI). Comp...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Saad Saleh Aldughaythir, Yousef Alolah, Mohsen Alzahrani, Fahad Abdulaziz Alsayed, Bader Muaykil Alqahtani, Omar Abdulrahman Alhathlol
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wolters Kluwer Medknow Publications 2017-01-01
Serie:	Journal of Applied Hematology
Soggetti:	Chronic myeloid leukemia compliance tyrosine kinase inhibitors
Accesso online:	http://www.jahjournal.org/article.asp?issn=1658-5127;year=2017;volume=8;issue=4;spage=140;epage=144;aulast=Aldughaythir
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!